Caris Life Sciences
CAI
27.10
-0.36
-1.29%
Caris Life Sciences
US · CAI
#1669 by market cap
Listed 2025
27.10
-0.36
-1.29%
Live - 5344 symbols - heartbeat 183s ago
· 2026-10-08 07:00
Pre-market
26.80
-1.11%
After-hours
27.10
0.00%
Overnight
26.88
-0.81%
- Market cap
- 7.66B
- P/E (TTM)i
- 72.85
- P/Bi
- 12.94
- EPSi
- -1.90
- Div yieldi
- 0.00%
- 52W posi
- 66%
Reader sentiment
Are you bullish or bearish on CAI?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 8 analysts
Buy
Avg price target
27.43 +1.2%
Price target rangecurrent 27.10
Low21.00
Avg27.43
High35.00
Buy 75%
Hold 25%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-20 | Goldman Sachs | -- | BUY | 35.00 |
| 2026-08-07 | BTIG | -- | BUY | 33.00 |
| 2026-08-06 | CCORF | -- | HOLD | 22.00 |
| 2026-08-06 | Piper Sandler | -- | HOLD | 21.00 |
| 2026-08-06 | BTIG | -- | BUY | 33.00 |
| 2026-08-06 | BofA Securities | -- | BUY | -- |
| 2026-08-06 | Evercore | -- | BUY | 26.00 |
| 2026-08-06 | J.P. Morgan | -- | BUY | 25.00 |
| 2026-07-22 | BTIG | -- | BUY | 32.00 |
| 2026-07-15 | TD Cowen | -- | BUY | 30.00 |
| 2026-07-13 | BofA Securities | -- | BUY | 23.00 |
| 2026-07-06 | Evercore | -- | BUY | 25.00 |
| 2026-07-02 | CCORF | -- | HOLD | 22.00 |
| 2026-07-02 | BTIG | -- | BUY | 32.00 |
| 2026-07-01 | Goldman Sachs | -- | BUY | 27.00 |
| 2026-06-01 | Wolfe Research | -- | HOLD | -- |
| 2026-05-13 | BofA Securities | -- | BUY | 28.00 |
| 2026-05-12 | Piper Sandler | -- | HOLD | 21.00 |
| 2026-05-09 | Evercore | -- | BUY | 30.00 |
| 2026-05-08 | TD Cowen | -- | BUY | 31.00 |
| 2026-05-08 | CCORF | -- | HOLD | 22.00 |
| 2026-05-08 | Piper Sandler | -- | HOLD | 21.00 |
| 2026-05-08 | Baird | -- | BUY | 22.00 |
| 2026-05-08 | Citi | -- | BUY | 28.00 |
| 2026-05-08 | J.P. Morgan | -- | BUY | 30.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1 1
■ Upgrades■ Downgrades
- 1 upgrade vs 1 downgrade among tracked analyst rating changes.
- Most recent: J.P. Morgan moved from Hold to Buy on 2026-05-08.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-05-08 | J.P. Morgan | HOLD → BUY | 30.00 |
| 2026-02-27 | J.P. Morgan | BUY → HOLD | 35.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | After close | ±19.22% | +21.58% (beat) |
| 2026/Q1 | 2026-05-07 | After close | ±14.87% | -18.60% (beat) |
| 2025/Q4 | 2026-02-26 | After close | ±22.61% | +4.68% (in line) |
| 2025/Q3 | 2025-11-05 | After close | ±20.71% | -15.75% (in line) |
| 2025/Q2 | 2025-08-12 | After close | -- | +5.61% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:00:15 · For reference only, not investment advice and not tailored to your situation.